The method of Chiou et al. 4 was used to predict theophylline kinetics in eleven critically ill patients with either acute severe asthma or bronchoconstriction. Following the commencement of an accurately metered infusion of aminophylline, venous blood samples were taken at approximately I, 5 hours and 7-12 hours for measurement of plasma theophylline concentration. The 1-and 5-hour levels were used to estimate total body clearance and plasma concentration of theophylline at the 7-12-hour sampling time. Using these values, the infusion rate was adjusted if necessaty and the protocol repeated. Initial predictions were unreliable in two patients because of continued absorption of theophylline from pre-infusion therapy with aminophylline suppositories or slowrelease theophylline tablets. In the remaining studies there was a significant correlation (y = 0.9x + 0.55, r2 = 0.93, p < 0.01, n = 19) between predicted and actual plasma concentrations at the 7-12-hour sampling time. In three patients, sequential estimates of theophylline clearance showed an approximate twofold variation and in another two patients, there was evidence of concentration-and/or time-dependent theophylline kinetics.
with this drug. Recently, several methods enabling rapid optimisation of oral 2 and intravenous 3 ,4,5 theophylline therapy have been reported. The method of Chiou et al. 4 has been shown to give robust estimates of total body clearance (TBC) for theophylline in patients with asthma or chronic obstructive pulmonary disease. 6 ,7 In these latter studies, estimates of TBC calculated from plasma concentration data obtained in the first few hours after starting intravenous therapy were compared with conventionally derived TBC values obtained when the patients had been on the infusion for long enough to have achieved steady-state plasma concentrations (approximately 5 half-lives). However, the pharmacokinetics of drug action may be profoundly altered and/or subject to temporal variation in critically ill patients 8 ,9 and in the present study we have evaluated the usefulness of the method of Chiou et al. 4 for short-term prediction of intravenous aminophylline dosage for patients in an intensive care unit (lCU).
METHODS
Patients. Eleven patients (5 men and 6 women) being cared for in the ICU were studied. They had a mean age of 50 years (range 17-79 years). Six were admitted because of acute exacerbation of their asthma while the remainder suffered from bronchoconstriction while in the ICU with other primary diagnoses.
The clinical details of each patient are shown in Table 1 .
Study Protocol. All patients were weighed on arrival in the ICU and a record of prior theophylline therapy was made. Aminophylline therapy was then initiated or continued using a slow intravenous infusion in 5070 dextrose solution via an IMED infusion pump usually commencing at a rate of 0.5 mg/kg/h. Two peripheral venous blood samples were obtained at approximately 1 and 5 hours after commencement of an infusion (tl and t2 respectively) and a third blood sample was taken at 7-12 hours (t3). In some studies, additional blood samples were also obtained at 2 and 4 hours after the start of the infusion. Plasma theophylline concentrations in these samples were estimated by high performance liquid chromatography (HPLC).
Measurement of Plasma Theophylline.
Plasma (0.1 ml) was prepared for chromatography by vortexing with 1 ml acetonitrile to precipitate protein and then the mixture was centrifuged. A 0.5 ml aliquot of the supernate was evaporated to dryness using a 6 .75 and 17.5 mg/l respectively, and the lower limit of detection was 0.5 mg/1. Pharmacokinetic Analyses. The method of Chiou et al. 4 was used to estimate TBC of theophylline (equation 1), based on the plasma concentrations C) and C 2 at times t) and t2 respectively after initiation of the constant rate infusion (k o ), and a population estimate 6 of 0.44 lIkg for volume of distribution (Vd. It should be noted that the method requires an accurate estimate of volume of distribution, and assumes that linear kinetics apply and that absorption of any previously administered theophylline is complete.
The plasma concentration at t3 was then predicted from equation 2: where K = TBC/V d (= first order elimination rate constant). This estimate of C3 was then able to be compared directly with the actual measured theophylline concentration at t3. Depending on the actual value of C3, and the therapeutically desirable plasma level (usually 10-20 mg/I), the dose regimen was modified if necessary. When the measured plasma theophylline concentration at C3 was substantially above the desired steady-state concentration (C ss *), the time (t) for which the infusion should be ceased to reach C ss * was calculated according to equation 3. When the measured C 3 was substantially below C ss *, the amount of a loading dose (administered over 15-30 min.) to achieve C ss * was calculated according to equation 4.
The new maintenance infusion rate (k o *) to maintain the C ss * level at the end of the period of cessation or following a loading dose infusion was calculated as: ko * = C ss *. TBC
Equation 5
When C 3 was not remarkably different from C ss * a new infusion rate was simply calculated using equation 5 and started at the earliest convenient time. After starting the infusion at the new rate, additional blood samples were collected using a similar sampling protocol. Four patients were studied on one occasion, four on two consecutive occasions and in three patients, three consecutive studies were made.
RESULTS
Details of aminophylline infusion rates and measured and predicted plasma theophylline concentrations at t3 are shown in Table 2 . Plasma concentrations obtained at relatively early times (t) and t2) after starting an infusion were used to predict concentration at a later time (t3)' Initial predictions were unreliable in patients 3 and 7 (+18.6 and +75.1% deviation) because of therapy with aminophylline suppositories (600 mg 1-3 hours before start of infusion) and slow release oral theophylline (300 mg 8 hours before start of infusion) respectively, given prior to admission to ICU. Excluding the initial data for these two patients, there was a significant (r2 = 0.93, p < 0.01) correlation between predicted and actual measured plasma concentrations at t3 ( Figure  1 ). Although individual percentage deviations ranged from -30 to 42%, of 19 predictions, 13 were within 15 % of the actual measured plasma concentration.
As a result of the predictions made using the plasma levels obtained at approximately 1 and 5 hours after starting the initial aminophylline infusion, there were several interventions to therapy. Four patients were given loading infusions of aminophylline followed by an increased maintenance infusion rate and in a fifth patient, an increase in maintenance infusion rate alone was considered appropriate. The initial infusion rate was decreased in another three patients and aminophylline therapy was ceased in one patient where plasma levels were in the toxic range at t3 (patient 8).
The effect of tl and t2 sampling times on the accuracy of prediction of plasma theophylline concentration at t3 was investigated retrospectively in 8 patients where plasma concentration data at approximately 1, 2, 4 and 5 hours were available ( Table 3) . Estimates of C3 based on the 1 and 2 hour data showed substantial deviations from actual values while estimates based on data at the other times were on average within 15070 of the actual value in three out of every four occasions.
In patient 8, an inappropriately high initial infusion rate resulted in a plasma level of 36.8 mg/l at 9.3 hours, at which time the infusion was stopped. Five further measurements of plasma theophylline concentrations were ( Figure 2) , it was apparent that this patient showed concentration-and/or timedependency of theophylline disposition. Patient 10 also showed evidence of concentrationrelated pharmacokinetic behaviour with a marked reduction in TBC when her plasma concentration was at the higher end of the usual therapeutic range. In patients 3, 4 and 11, there were marked variations in estimated TBC at different times but these were not able to be related to either dose or plasma level. Loading doses of aminophylline were administered on four occasions (Table 4 ) and the difference between the actual plasma theophylline and the desired concentrations at the end of the loading infusion ranged from -6070 to + 49%. Overall, there were only two occasions on which an aminophylline infusion was ceased because the measured plasma theophylline concentration was too high ( Table  5 ). For patient 8, the actual level after 26 hours was 44070 below the level predicted assuming linear kinetics while for patient 10, actual and predicted varied by only 15 %.
DISCUSSION
In any pharmacokinetic study, appropriately spaced and accurately measured sampling times are essential. The protocol used in our study required initial plasma samples at 1 and 5 hours after commencing an aminophylline infusion with an additional sample collected subsequently. In several of the studies, additional samples were also collected at 2 and 4 hours. We had few problems with accurate measurement and recording of sampling times, and in most cases were able to obtain samples at the desired times. However, in some patients, non-standard times had to be accepted for various reasons associated with practical patient care in the ICD. Where multiple samples were collected in the first 5 hours and there were no reasons to question the reliability of the data, we have quantified the influence of using various Cl and C2 data pairs on the plasma level predictions made using the method of Chiou et al. 4 As might be expected, predictions using the 1 and 2 hour data were highly variable; in most cases, maximum rate of change in plasma concentration would occur in this period and hence even slight inaccuracies in sampling times, concentration measurements, or estimation of volume of distribution could cause considerable error in pharmacokinetic predictions. 4 There was little to choose between the other sampling time pairs, all of which yielded predicted theophylline levels (at t3) with Anaesthesia and Intensive Care. Vol. 11, No. 3, Augllsl, /983 mean absolute per cent deviations from the actual level ranging from 5.6-10.2%.
When the predicted levels at t3 were considered, there was a significant (p < 0.01) correlation with the actual measured theophylline concentrations (Figure 1 ). Substantial deviations in predicted data for two patients highlighted the influence of previous theophylline therapy on the pharmacokinetic method. In these patients, continuing absorption from recent therapy with either slow-release oral theophyllilne or aminophylline suppositories resulted in underestimation of TBC and overestimation of the theophylline concentration at t3. Provided that this limitation of the method is recognised, it can provide a rapid and reasonably accurate means of adjusting intravenous aminophylline therapy in the short term. Previous workers 6 .7 have shown that the method gives robust estimates of steady-state TBe. Anderson et al. 6 showed a highly significant correlation (r=0.858, p < 0.001, n= 19) between the estimated clearance and the actual clearance calculated from the steady-state plasma concentration and the infusion rate. In the study by Vozeh et al.,7 actual and estimated clearance values differed by only 1 % (mean, SD 14%, n = 15) while actual and predicted plasma concentrations at steady state differed by only -0.22 (SD 1.97) mg/1.
The TBC estimate for theophylline in three patients showed an approximately twofold variation in sequential data obtained over a 24-72 hour period. The reas()ns for this variability were not apparent from biochemical indices of hepatic or renal function. The TBC for theophylline is known to be reduced in patients with acute airway obstruction 1.8 and factors such as hypoxemia or acidosis could be possible causes of altered theophylline disposition. However, we were unable to find any marked alteration in P02 or plasma pH which correlated with time-related changes in TBC in our patients. In addition plasma theophylline concentrations have recently been reported to be depressed during isoprenaline infusion. 1l All of our patients who exhibited variability in theophylline TBC also received the related beta-adrenoceptor agonist salbutamol (by nebulizer) but this therapy did not correlate with the TBC changes. We presume that the changes in TBC reflect more subtle but nevertheless significant time-related alterations in other factors controlling theophylline disposition. Hence, although optimisation of therapy was achieved in the short term, in a routine therapeutic situation further measurements of plasma theophylline at frequent regular intervals would be needed to update the pharmacokinetic information and thereby maintain plasma levels within the desired range.
Calculation of appropriate loading infusions was satisfactory in most cases. In three of the patients, actual values for plasma theophylline at the end of the loading infusion were below those desired (-2 to -60/0). This occurred because the loading infusion was administered over 15-30 minutes, whereas the method of calculating the loading dose assumed instantaneous input. Patient 1 was obese (lOO kg), and showed an actual theophylline concentration which was 49% greater than that desired, most probably because of overestimation of Vd for theophylline. Calculation of cessation time where plasma level was inappropriately high was satisfactory in one patient (10) but showed substantial deviation in patient 8 who also demonstrated non-linear kinetic behaviour.
The method used in the present study assumes linear pharmacokinetics. 4 Studies of theophylline metabolism in man I2 have demonstrated saturability of the 3-methylxanthine pathway and clinical studies in children I3 , 14 have demonstrated non-linear kinetics. However, in adults, dose-dependency of theophylline kinetics has not been shown at plasma concentrations below the upper end of the usual therapeutic range. 15 ,16,17 In the present study, non-linear behaviour of theophylline at plasma concentrations in the 13-37 mg/l range was clearly demonstrated in patient 8. Patient 10 also showed an approximate 43 % reduction in TBC at a time when her plasma concentration had risen to the upper end of the usual therapeutic range. While these patients' data are consistent with non-linear behaviour, they could equally well be explained by timedependent changes in theophylline disposition. It is of interest to note that dose-dependency of theophylline kinetics at toxic plasma concentrations has been previously reported in a 72-year-old man l and a 3-year-old child. 13 In summary, the study shows that our application of the method of Chiou et aI, 4 provides good short-term predictions of plasma theophylline concentrations in this patient group. Rational, data-based adjustments to intravenous aminophylline therapy can be made at an early time about 7 hours after starting an infusion. Non-linearity or timedependency of theophylline kinetics was observed in some patients and thus estimates of TBC may only be reliable in an approximate 12-24-hour period after their determination. Nevertheless, administering intravenous aminophylline in this manner minimises erratic and sometimes dangerous plasma theophylline levels commonly seen with fixed-dose regimes. In our view, successful use of the method requires the participation of an experienced pharmacologist to assist with data analysis and interpretation of results.
